Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Cash from Operations: 2017-2024

Historic Cash from Operations for DiaMedica Therapeutics (DMAC) over the last 8 years, with Dec 2024 value amounting to -$22.1 million.

  • DiaMedica Therapeutics' Cash from Operations rose 1.84% to -$1.9 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$9.1 million, marking a year-over-year decrease of 59.80%. This contributed to the annual value of -$22.1 million for FY2024, which is 18.01% down from last year.
  • As of FY2024, DiaMedica Therapeutics' Cash from Operations stood at -$22.1 million, which was down 18.01% from -$18.7 million recorded in FY2023.
  • In the past 5 years, DiaMedica Therapeutics' Cash from Operations ranged from a high of -$9.2 million in FY2020 and a low of -$22.1 million during FY2024.
  • Moreover, its 3-year median value for Cash from Operations was -$18.7 million (2023), whereas its average is -$17.4 million.
  • Per our database at Business Quant, DiaMedica Therapeutics' Cash from Operations increased by 6.05% in 2022 and then tumbled by 62.70% in 2023.
  • DiaMedica Therapeutics' Cash from Operations (Yearly) stood at -$9.2 million in 2020, then plummeted by 33.39% to -$12.3 million in 2021, then climbed by 6.05% to -$11.5 million in 2022, then plummeted by 62.70% to -$18.7 million in 2023, then fell by 18.01% to -$22.1 million in 2024.